Modified CMVgB protein and CMV vaccine containing the same
CN112888455BActive Publication Date: 2024-12-24KM BIOLOGICS CO
Patent Information
- Application Number
- CN201980069323.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-10-25
- Filing Date
- 2019-10-24
- Publication Date
- 2024-12-24
- Estimated Expiration
- 2039-10-24
Smart Images

Figure GDA0003029440110000181 
Figure GDA0003029440110000211 
Figure GDA0003029440110000221
Abstract
The object of the present invention is to provide a modified CMV gB protein and a CMV vaccine comprising the same, wherein the modified CMV gB protein can induce a high-content antibody group of neutralizing antibodies showing high neutralizing activity against CMV gB protein during immune induction compared with wild-type CMV gB, and can be used to prevent and / or treat CMV infection. The modified CMV gB protein of the present invention is a modified CMV gB protein that includes a modification in the head region and has an improved ability to induce antibodies in the body region.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Genetically modified ecarin and process for producing the same
WO2003004647A1
Novel antigen
WO2012049317A2
Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines
WO2015089340A1
Anti-transthyretin humanized antibody
WO2015115331A1
Chimeric molecules and uses thereof
CN110506060A
